Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Philippines to seek...

    Philippines to seek refund of 59 million dollars from Sanofi amid vaccine risk

    Written by Ruby Khatun Khatun Published On 9 Dec 2017 5:00 AM  |  Updated On 16 Aug 2021 11:38 AM

    MANILA: The Philippines will seek the return of 3 billion pesos ($59 million) it paid French drugmaker Sanofi for a dengue vaccine used to immunize hundreds of thousands of children that Sanofi has said could worsen the disease in some cases.


    "We will demand the refund of the 3 billion (pesos) paid for the Dengvaxia and (demand) that Sanofi set up an indemnification fund to cover the hospitalization and medical treatment of all children who might have severe dengue," Health Secretary Francisco Duque told reporters on Friday.


    The Philippines last week suspended a national immunization programme after Sanofi's recent findings that there was a risk of severe dengue occurring in previously uninfected people who were inoculated with Dengvaxia. Manila also halted the sale of the vaccine in the country and has ordered a probe into the matter.


    Duque said the number of children, ages 9 and above, inoculated with Dengvaxia has risen to about 830,000 from an initial estimate of nearly 734,000 after further verification by the Department of Health.


    The state programme, which was launched in 2016, cost 3.5 billion pesos and Duque earlier said the government has already paid 3 billion pesos to Sanofi.


    Sanofi's Philippines office did not immediately respond to a request for comment.


    Sanofi officials said on Monday in Manila that there had been no reported deaths related to the vaccine.


    Duque, citing the drugmaker's disclosure and studies, said Dengvaxia was meant to provide 30-month protection against dengue to those vaccinated, including those who did not have any prior dengue infection.


    But he said the case of a 12-year old girl in Tarlac province, north of the capital Manila, who completed the three-dose vaccine treatment and showed symptoms of severe dengue, seemed to have defied that.


    She was first inoculated with Dengvaxia in March 2016 and received the third and last dose in August this year, the health minister said.


    Asked whether the case showed the effectiveness of the vaccine was questionable, Duque said: "Most certainly."


    Dengue is a mosquito-borne tropical disease that kills about 20,000 people a year and infects hundreds of millions.


    ($1 = 50.5350 Philippine pesos)




    (Reporting by Manolo Serapio Jr.; Additional reporting by Neil Jerome Morales; Editing by Raju Gopalakrishnan)



    DengueDengue vaccineDengvaxiaDepartment of HealthFrancisco DuqueManilaPhilippinesrefundSanofivaccine
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok